Exelixis (EXEL) Tops Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to Exelixis (EXEL) Tops Q2 EPS by 12c

Exelixis Announces Second Quarter 2018 Financial Results and Provides Corporate Update

August 1, 2018 4:05 PM EDT

- Total Revenues of $186.1 million, Net Income of $87.5 million, Diluted EPS of $0.28 -

- Cabozantinib Franchise Net Product Revenues of $145.8 million -

- Ipsen Royalty Rate Increased to 22 Percent upon Reaching $150.0 million in Cumulative Net Sales -

- Conference Call and Webcast Today at 5:00 P.M. Eastern Daylight Time -

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2018 and provided an update on progress toward fulfilling its... More